The DOI matches its Crossref record.
C-Peptide Replacement Therapy and Sensory Nerve Function in Type 1 Diabetic Neuropathy
Open accessAbstract
OBJECTIVE—C-peptide replacement in animals results in amelioration of diabetes-induced functional and structural abnormalities in peripheral nerves. The present study was undertaken to examine whether C-peptide administration to patients with type 1 diabetes and peripheral neuropathy improves sensory nerve function. RESEARCH DESIGN AND METHODS—This was an exploratory, double-blinded, randomized, and placebo-controlled study with three study groups that was carried out at five centers in Sweden. C-peptide was given as a replacement dose (1.5 mg/day, divided into four subcutaneous doses) or a dose three times higher (4.5 mg/day) during 6 months. Neurological examination and neurophysiological measurements were performed before and after 6 months of treatment with C-peptide or placebo. RESULTS—The age of the 139 patients who completed the protocol was 44.2 ± 0.6 (mean ± SE) years and their duration of diabetes was 30.6 ± 0.8 years. Clinical neurological impairment (NIA) (score >7 points) of the lower extremities was present in 86% of the patients at baseline. Sensory nerve conduction velocity (SCV) was 2.6 ± 0.08 SD below body height–corrected normal values at baseline and improved similarly within the two C-peptide groups (P < 0.007). The number of patients responding with a SCV peak potential improvement >1.0 m/s was greater in C-peptide–treated patients than in those receiving placebo (P < 0.03). In the least severely affected patients (SCV < 2.5 SD below normal at baseline, n = 70) SCV improved by 1.0 m/s (P < 0.014 vs. placebo). NIA score and vibration perception both improved within the C-peptide–treated groups (P < 0.011 and P < 0.002). A1C levels (7.6 ± 0.1% at baseline) decreased slightly but similarly in C-peptide–and placebo-treated patients during the study. CONCLUSIONS—C-peptide treatment for 6 months improves sensory nerve function in early-stage type 1 diabetic neuropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Islet Amyloid Polypeptide, Islet Amyloid, and Diabetes Mellitus
Westermark, P., Andersson, A., & Westermark, G. T. (2011) · Physiological Reviews · doi:10.1152/physrev.00042.2009 · Cited by 1,044
Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy
Sloan, G., Selvarajah, D., & Tesfaye, S. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00496-z · Cited by 534
Implementing a reference measurement system for C-peptide: successes and lessons learned
Little, R. R., Wielgosz, R. I., Josephs, R., Kinumi, T., Takatsu, A., Li, H., Stein, D., & Burns, C. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2016.269274 · Cited by 383
Halkos, M. E., Puskas, J. D., Lattouf, O. M., Kilgo, P., Kerendi, F., Song, H. K., Guyton, R. A., & Thourani, V. H. (2008) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2008.02.091 · Cited by 299
Diabetic Painful and Insensate Neuropathy: Pathogenesis and Potential Treatments
Obrosova, I. G. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2009.07.004 · Cited by 272
Metadata
- Authors
- Ekberg, K., Brismar, T., Johansson, B.-L., Lindström, P., Juntti-Berggren, L., Norrby, A., Berne, C., Arnqvist, H. J., Bolinder, J., & Wahren, J.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2007-01-01
- Volume
- 30
- Issue
- 1
- Pages
- 71-76
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2110053371
- Cited by
- 163
- References
- 0
- FWCI
- 8.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: C-Peptide Replacement Therapy and Sensory Nerve Function in Type 1 Diabetic Neuropathy. https://app.cochat.ai/papers/10.2337/dc06-1274
- The paper
- Ekberg, K., Brismar, T., Johansson, B.-L., Lindström, P., Juntti-Berggren, L., Norrby, A., Berne, C., Arnqvist, H. J., Bolinder, J., & Wahren, J. (2007). C-Peptide Replacement Therapy and Sensory Nerve Function in Type 1 Diabetic Neuropathy. Diabetes Care. https://doi.org/10.2337/dc06-1274
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.